Logo image of ALBLU.PA

BLUELINEA (ALBLU.PA) Stock Fundamental Analysis

EPA:ALBLU - Euronext Paris - Matif - FR0011041011 - Common Stock - Currency: EUR

0.615  -0.02 (-3.15%)

Fundamental Rating

1

ALBLU gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 59 industry peers in the Health Care Equipment & Supplies industry. ALBLU may be in some trouble as it scores bad on both profitability and health. ALBLU is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

ALBLU had negative earnings in the past year.
In the past year ALBLU had a positive cash flow from operations.
ALBLU had negative earnings in each of the past 5 years.
ALBLU had a negative operating cash flow in each of the past 5 years.
ALBLU.PA Yearly Net Income VS EBIT VS OCF VS FCFALBLU.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1M -2M -3M -4M

1.2 Ratios

The Return On Assets of ALBLU (-16.32%) is worse than 67.80% of its industry peers.
ALBLU has a Return On Equity of -115.32%. This is amonst the worse of the industry: ALBLU underperforms 83.05% of its industry peers.
Industry RankSector Rank
ROA -16.32%
ROE -115.32%
ROIC N/A
ROA(3y)-22.53%
ROA(5y)-28.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALBLU.PA Yearly ROA, ROE, ROICALBLU.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200 -300

1.3 Margins

With an excellent Gross Margin value of 103.22%, ALBLU belongs to the best of the industry, outperforming 96.61% of the companies in the same industry.
ALBLU's Gross Margin has been stable in the last couple of years.
ALBLU does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 103.22%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.66%
GM growth 5Y1.04%
ALBLU.PA Yearly Profit, Operating, Gross MarginsALBLU.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50

0

2. Health

2.1 Basic Checks

ALBLU does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALBLU remains at a similar level compared to 1 year ago.
Compared to 5 years ago, ALBLU has more shares outstanding
ALBLU has a worse debt/assets ratio than last year.
ALBLU.PA Yearly Shares OutstandingALBLU.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
ALBLU.PA Yearly Total Debt VS Total AssetsALBLU.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -2.94, we must say that ALBLU is in the distress zone and has some risk of bankruptcy.
ALBLU has a worse Altman-Z score (-2.94) than 83.05% of its industry peers.
A Debt/Equity ratio of 2.31 is on the high side and indicates that ALBLU has dependencies on debt financing.
The Debt to Equity ratio of ALBLU (2.31) is worse than 83.05% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.31
Debt/FCF N/A
Altman-Z -2.94
ROIC/WACCN/A
WACC6.79%
ALBLU.PA Yearly LT Debt VS Equity VS FCFALBLU.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M -4M 6M 8M

2.3 Liquidity

A Current Ratio of 0.49 indicates that ALBLU may have some problems paying its short term obligations.
With a Current ratio value of 0.49, ALBLU is not doing good in the industry: 88.14% of the companies in the same industry are doing better.
ALBLU has a Quick Ratio of 0.49. This is a bad value and indicates that ALBLU is not financially healthy enough and could expect problems in meeting its short term obligations.
ALBLU has a Quick ratio of 0.44. This is amonst the worse of the industry: ALBLU underperforms 84.75% of its industry peers.
Industry RankSector Rank
Current Ratio 0.49
Quick Ratio 0.44
ALBLU.PA Yearly Current Assets VS Current LiabilitesALBLU.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 19.35% over the past year.
ALBLU shows a decrease in Revenue. In the last year, the revenue decreased by -5.60%.
The Revenue has been growing by 9.78% on average over the past years. This is quite good.
EPS 1Y (TTM)19.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.56%
Revenue 1Y (TTM)-5.6%
Revenue growth 3Y12.92%
Revenue growth 5Y9.78%
Sales Q2Q%-6.48%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALBLU.PA Yearly Revenue VS EstimatesALBLU.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
ALBLU.PA Yearly EPS VS EstimatesALBLU.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 -0.1 -0.2 -0.3

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALBLU. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALBLU.PA Price Earnings VS Forward Price EarningsALBLU.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ALBLU is on the same level as its industry peers.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 38.91
ALBLU.PA Per share dataALBLU.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for ALBLU!.
Industry RankSector Rank
Dividend Yield N/A

BLUELINEA

EPA:ALBLU (6/18/2025, 7:00:00 PM)

0.615

-0.02 (-3.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners83.76%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap7.55M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.79
P/FCF N/A
P/OCF 24.65
P/B 5.17
P/tB N/A
EV/EBITDA 38.91
EPS(TTM)-0.14
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)0.02
OCFY4.06%
SpS0.77
BVpS0.12
TBVpS-0.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.32%
ROE -115.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 103.22%
FCFM N/A
ROA(3y)-22.53%
ROA(5y)-28.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.66%
GM growth 5Y1.04%
F-Score5
Asset Turnover0.92
Health
Industry RankSector Rank
Debt/Equity 2.31
Debt/FCF N/A
Debt/EBITDA 13.16
Cap/Depr 144.22%
Cap/Sales 27.72%
Interest Coverage N/A
Cash Conversion 119.5%
Profit Quality N/A
Current Ratio 0.49
Quick Ratio 0.44
Altman-Z -2.94
F-Score5
WACC6.79%
ROIC/WACCN/A
Cap/Depr(3y)140.81%
Cap/Depr(5y)112.84%
Cap/Sales(3y)19.23%
Cap/Sales(5y)15.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.56%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-5.6%
Revenue growth 3Y12.92%
Revenue growth 5Y9.78%
Sales Q2Q%-6.48%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-232.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y921.33%
OCF growth 3YN/A
OCF growth 5YN/A